Piramal Pharma Limited (NSE:PPLPHARMA)

Revenue by Product

Fiscal year is April - March.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Contract Development and Manufacturing Organisation	47.39B	Log In	Log In
Inhalation Anesthesia	16.42B	Log In	Log In
Inhalation Anesthesia Growth	13.25%	Log In	Log In
Intrathecal Therapy	3.68B	Log In	Log In
Intrathecal Therapy Growth	8.17%	Log In	Log In
Injectable Anesthesia and Pain Management	2.45B	Log In	Log In
Injectable Anesthesia and Pain Management Growth	-1.66%	Log In	Log In
Kids Wellness	2.26B	Log In	Log In
Kids Wellness Growth	20.63%	Log In	Log In
Other Generic and Specialty Products	1.96B	Log In	Log In
Other Generic and Specialty Products Growth	-13.46%	Log In	Log In
Skin Care	1.86B	Log In	Log In
Skin Care Growth	4.40%	Log In	Log In
Analgesic	1.86B	Log In	Log In
Multivitamin	1.47B	Log In	Log In
Other	2.35B	Log In	Log In
Other Growth	-51.42%	Log In	Log In
Commercial Manufacturing	-	Log In	Log In
Development Services	-	Log In	Log In
Discovery Services	-	Log In	Log In
Global Pharma	-	Log In	Log In
Over the Counter Products	-	Log In	Log In
Miscellaneous	-	Log In	Log In
Other	2.35B	Log In	Log In
Other Growth	-51.42%	Log In	Log In

Revenue by Geography

Fiscal year is April - March.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Other	8.17B	Log In	Log In
Other Growth	4.90%	Log In	Log In
North America	33.50B	Log In	Log In
North America Growth	5.13%	Log In	Log In
Europe	20.43B	Log In	Log In
Europe Growth	44.23%	Log In	Log In
India	16.34B	Log In	Log In
India Growth	15.39%	Log In	Log In
Japan	3.27B	Log In	Log In
Japan Growth	15.39%	Log In	Log In
Other	8.17B	Log In	Log In
Other Growth	4.90%	Log In	Log In